Castle Biosciences FY 2024 revenue up 51% to $332M, net income $18.2M vs loss; 2025 outlook $280-295M

CASTLE BIOSCIENCES INC

2024-FY EPS reported $0.62 revenue$332,069,000

Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).
Net income $18.2M (incl. $50.3M stock comp) vs net loss $57.5M in 2023.
Adjusted EBITDA $75.0M vs -$4.4M in 2023; cash $293.1M, up $50M.
TissueCypher Barrett's Esophagus test reports surged 130% to 20,956; dermatology reports up 17%.
2025 revenue guidance $280-295M, below 2024 actual but achieved prior 2025 target a year early.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.